Corporate News Report: Enveric Biosciences Market Performance and Peer Comparison
Enveric Biosciences (NASDAQ: ENVB) closed the trading session on Thursday, 22 October 2026, at a 4.86 % gain, reaching a price of USD 1.51. The rise came within a 24‑hour window that concluded at 06:03 PM Central Europe. With a market capitalization of USD 6.8 million and a total share supply of 4.5 million shares, the company’s recent activity shows a modest turnover of USD 127.6 thousand in the last day.
The stock’s performance has fluctuated markedly over the past month. Since the previous month’s end, Enveric Biosciences has experienced a decline of 1.95 %, underscoring the volatility that often characterizes small‑cap biotech firms. A look at longer‑term metrics provides additional context: the 200‑day simple moving average currently sits at USD 2.11, well above the current price, while the all‑time high over the past 52 weeks was USD 13.25 on 10 December 2025. The 52‑week low, recorded on 26 August 2026, was USD 1.17.
Peer Performance Snapshot (Last 24 Hours)
| Company | Ticker | 24‑hr Movement | Current Price (USD) | Market Capitalisation (USD) | Notable Recent News |
|---|---|---|---|---|---|
| Soligenix | SNGX | Flat (0 %) | 0.36 | 7.7 million | — |
| Ciso Global | CISO | Down (–0.57 %) | 0.17 | 7.9 million | Launched a quantitative cyber‑risk platform linking security gaps to projected financial loss. |
| Biomerica | BMRA | Down (–0.58 %) | 1.66 | 7.9 million | — |
| Curanex | CURX | Up (5.14 %) | 4.99 | 7.9 million | — |
| Calcimedica | CALC | Up (7.98 %) | 1.22 | 8.1 million | — |
The data reveal that while Enveric’s price increased, its peers exhibited a mixed picture. Curoex and Calcimedica posted gains comparable to or exceeding Enveric’s, whereas Soligenix, Ciso Global, and Biomerica registered modest declines.
Company Overview
Enveric Biosciences, Inc. is headquartered in Naples and focuses on developing novel small‑molecule therapeutics aimed at treating anxiety, depression, and addiction disorders. Beyond its core research and development activities, the company offers information technology services to clients across the United States and Canada. Enveric’s listing on the Nasdaq exchange and its publicly available information—including corporate disclosures on its website at www.enveric.com —provide stakeholders with transparent access to its operations and financial health.
This report synthesises the most recent market activity and situates Enveric Biosciences within the broader biotech and technology sectors, offering investors a concise yet comprehensive view of its current standing.
